WilliamHenryLudlamMD

Diabetes, Lipid Metabolism

Physician

Dr. Ludlam is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
550 17th Ave
Ste 500
Seattle, WA 98122
Phone+1 206-320-2800

Fax+1 206-320-3153

Oregon Health & Science University (OHSU Health)Fellowship, Endocrinology, Diabetes, and Metabolism, 1997 - 1999
Oregon Health & Science University (OHSU Health)Residency, Internal Medicine, 1995 - 1997
Albert Einstein College of MedicineClass of 1995

PubMed

8 citations
Durable biochemical response and safety with oral octreotide capsules in acromegaly.
Susan L Samson, Lisa B Nachtigall, Maria Fleseriu, Mojca Jensterle, Patrick J Manning
European Journal of Endocrinology. 2022-12-01
17 citations
Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised contr...
Maria Fleseriu, Alexander Dreval, Irina Bondar, Gulnar Vagapova, Djuro Macut
The Lancet. Diabetes & Endocrinology. 2022-02-01
54 citations
Maintenance of Acromegaly Control in Patients Switching From Injectable Somatostatin Receptor Ligands to Oral Octreotide.
Susan L. Samson, Lisa B. Nachtigall, Maria Fleseriu, Murray B. Gordon, Marek Bolanowski
The Journal of Clinical Endocrinology and Metabolism. 2020-10-01

AstraZeneca Promotes Oncology Exec to CMO; Pfizer Replaces Retiring Chief Dealmaker as War Chest ExpandsAugust 27th, 2021
Chutes & Ladders—Pfizer Taps McKinsey U.S. Managing Partner as New M&a LeaderAugust 27th, 2021
Recordati Rare Diseases Announces William Ludlam, MD, PhD, as New Chief Medical Officer and Vice President - Clinical DevelopmentAugust 25th, 2021
Join now to see all